Celgene Corporation is a drug manufacturers - general business based in the US. Celgene Corporation shares (CELG) are listed on the NASDAQ and all prices are listed in US Dollars. Celgene Corporation employs 8,852 staff and has a trailing 12-month revenue of around $17 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| 52-week range | $0.00 - $0.00 |
|---|---|
| 50-day moving average | $108.24 |
| 200-day moving average | $104.36 |
| Wall St. target price | $103.40 |
| PE ratio | 13.33 |
| Dividend yield | N/A |
| Earnings per share (TTM) | $8.13 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Celgene Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Celgene Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Celgene Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 13x. In other words, Celgene Corporation shares trade at around 13x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Celgene Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.86. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Celgene Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Celgene Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $8.9 billion.
The EBITDA is a measure of a Celgene Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $17 billion |
|---|---|
| Operating margin TTM | 48.75% |
| Gross profit TTM | $14.1 billion |
| Return on assets TTM | 13.69% |
| Return on equity TTM | 69.39% |
| Profit margin | 34.63% |
| Book value | $16.99 |
| Market Capitalization | $77 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Celgene Corporation.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 23.71
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Celgene Corporation's overall score of 23.71 (as at 12/31/2018) is excellent – landing it in it in the 3rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Celgene Corporation is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 1.02/100
Celgene Corporation's environmental score of 1.02 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14.4/100
Celgene Corporation's social score of 14.4 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Celgene Corporation is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 5.29/100
Celgene Corporation's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Celgene Corporation is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Celgene Corporation scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Celgene Corporation has, for the most part, managed to keep its nose clean.
Celgene Corporation was last rated for ESG on: 2019-01-01.
| Total ESG score | 23.71 |
|---|---|
| Total ESG percentile | 2.75 |
| Environmental score | 1.02 |
| Environmental score percentile | 2 |
| Social score | 14.4 |
| Social score percentile | 2 |
| Governance score | 5.29 |
| Governance score percentile | 2 |
| Level of controversy | 2 |
We're not expecting Celgene Corporation to pay a dividend over the next 12 months.
Celgene Corporation's shares were split on a 2:1 basis on 25 June 2014 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Celgene Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Celgene Corporation shares which in turn could have impacted Celgene Corporation's share price.
Over the last 12 months, Celgene Corporation's shares have ranged in value from as little as $0 up to $0. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Celgene Corporation's is 1.4131. This would suggest that Celgene Corporation's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (rrAML) with an isocitrate dehydrogenase-2 mutation; VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; THALOMID to treat patients with MM; and ISTODAX, an epigenetic modifier. Its preclinical and clinical-stage product candidates include small molecules, biologics, and cell therapies for immune-inflammatory diseases, myeloid diseases, epigenetics, protein homeostasis, and immuno-oncology. The company has agreements with BeiGene, Ltd; Acceleron Pharma, Inc. ; Agios Pharmaceuticals, Inc. ; bluebird bio, Inc.
Some of the best paper trading apps to practice stock trading with fake money include Interactive Brokers, eToro, Charles Schwab and more.
Want to buy and sell international stocks? Here are the top brokers to help you trade global markets.
These are the best discount brokers of 2024 according to Finder’s comprehensive review.
The best platforms to use for automatic investing include Wealthfront, SoFi, Schwab, Vanguard, Titan, Acorns and more. See our full list here.
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
5 Betterment robo-advisor alternatives to consider when building your portfolio.
What you need to know about investing in the leading indicator for the overall US stock market.
How do you gift stocks to loved ones? Learn the ins and outs of finding the right investments for them.
Check out the best-performing ETFs so far in 2024.
Acorns is a financial service that rounds up your purchases and turns the extra change into investments.